BioRegenx FCF per Share
Free Cash Flow per Share of BioRegenx (BRGX) as of Oct 12, 2026.
Get this data via API
Financial Data API
FCF per Share
0.00USD
YoY
-105.75%
Last updated:
Free Cash Flow per Share of BioRegenx is 2025 0.00 USD. Free Cash Flow per Share of BioRegenx was 2024 -0.00 USD. It decreases by -105.75% higher compared to the previous year.
The BioRegenx FCF per Share history
3 Years
10 Years
25 Years
Max
FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
0.00 USD
| YEAR | FCF per Share | YoY |
|---|---|---|
| 0.00USD | -105.75% | |
| -0.00USD | +136.82% | |
| -0.00USD | -5.46% | |
| -0.00USD | -57.20% | |
| -0.00USD | +63.44% | |
| -0.00USD | +133.42% | |
| -0.00USD | +151.02% | |
| -0.00USD | +0.70% | |
| -0.00USD | — |
Access this data via the Eulerpool API
BioRegenx Stock analysis
What does BioRegenx do? Findit Inc is a company that was founded in 1998 and is headquartered in Atlanta, Georgia. It specializes in providing online marketing and social media solutions. Findit Inc is a publicly traded company and is listed on the OTC market under the symbol FDIT. BioRegenx is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BioRegenx stock
On Eulerpool you can find the complete historical development of Free Cash Flow per Share BioRegenx since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
Cash Flow — BioRegenx
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — BioRegenx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth